Roche welcomes you to the webinar

The role of bispecifics in 3L DLBCL with focus on Columvi®▼(glofitamab)

Date: 23 May 2024
Time: 16:00-18:00

This invitation is for doctors and nurses with an interest in lymphoma.
A copy of the invitation is sent to the healthcare operations manager.

We are pleased to extend an invitation for you to attend our webinar: **The role of bispecifics in 3L DLBCL with focus on Columvi (glofitamab)** on the 23rd of May, 2024.

AGENDA

Time	Topic	Speaker
16:00-16:10	**Welcome and introduction to treatment landscape 3L DLBCL**	Prof. Sirpa Leppä
16:10-16:55	**Clinical data Columvi**	Prof. Martin Hutchings
16:55-17:30	**Patient cases Columvi**	Prof. Georg Lenz
17:30-17:55	**Nordic discussion and questions from the chat**	Moderated by Prof. Sirpa Leppä Prof. Martin Hutchings Prof. Georg Lenz Dr. Alexander Fosså Assoc. Prof. Ola Lindén
17:55	**Webinar close**	Prof. Sirpa Leppä
18:00	**End**	

You can join the webinar from anywhere, using your computer, laptop, iPad or mobile phone. This webinar will be given in English.

Register for the event

Please use the link to register: https://go.roche.com/nordicwebinar

When you submit your registration, you will receive an confirmation e-mail with webinar details. You will also receive a reminder prior to the event.

The consignment is sent with the support of information from Hälso och Sjukvårdens Adressregister, HSAR, by Roche AB, which is connected to the Swedish Integrity protection program, Intregritetsskyddsprogrammet, for HSAR. Further information is obtained from IQVIA Solution Sweden AB, e-mail: adressuppdatering@iqvia.com.

SPEAKERS

Sirpa Leppä is a professor of clinical oncology at the University of Helsinki and a chief physician at the Helsinki University Hospital Comprehensive Cancer Centre. She is also a chair of the Nordic lymphoma group. Her special research interests are to develop and optimise treatments for lymphoma patients and to identify biologically relevant prognostic factors.

Georg Lenz is a professor and Director of the Department of Hematology, Oncology, and Pneumology at the University Hospital in Muenster, Germany, as well as president of the German Lymphoma Alliance. His research delves into the molecular characterization of malignant lymphomas and the efficacy of novel therapies for patients, with significant contributions in esteemed peer-reviewed journals and books.

Alexander Fosså, MD PhD, is a senior consultant oncologist at the department of oncology at Oslo University Hospital. He is head of the lymphoma research group in Oslo, and leads the Norwegian lymphoma group. Since 2013, he has served as head of the Nordic Hodgkin lymphoma working group.

Martin Hutchings is a haemato-oncologist and a senior consultant from the Department of Haematology, Rigshospitalet, Copenhagen University Hospital and a professor of haematology at the University of Copenhagen. He is responsible for lymphoma treatment and clinical research and leads Denmark's only dedicated Phase 1 unit for experimental treatment of haematological malignancies, which is a leading site for early development of lymphoma immunotherapy.

Ola Lindén, MD Associate Professor, is a senior consultant oncologist at the department of oncology at Lund University Hospital. He is chairman of the national guideline group follicular lymphoma and hairy cell leukaemia and has been a board member at the Swedish lymphoma group.

COLUMVI®▼ (glofitamab) 2.5 mg and 10 mg concentrate for solution for infusion. Humanised anti-CD20/anti-CD3 bispecific monoclonal antibody. L01FX (Rx, EF). Summary of Product Characteristics updated 2024-01-03. Therapeutic indications: COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Special warnings and precautions for use: Cytokine release syndrome (CRS), serious infections, tumour flare, tumour lysis syndrome (TLS). For detailed description of warnings and precautions see www.fass.se. Contraindications: Hypersensitivity to the active substance, to obinutuzumab, or to any of the excipients. For more information see Summary of Product Characteristics, www.fass.se.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting must be done to Läkemedelsverket, www.lakemedelsverket.se or direct to Roche at sverige.safety@roche.com or by telephone number 08-726 12 00.

M-SE-00001098